JP2018527287A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527287A5
JP2018527287A5 JP2017560611A JP2017560611A JP2018527287A5 JP 2018527287 A5 JP2018527287 A5 JP 2018527287A5 JP 2017560611 A JP2017560611 A JP 2017560611A JP 2017560611 A JP2017560611 A JP 2017560611A JP 2018527287 A5 JP2018527287 A5 JP 2018527287A5
Authority
JP
Japan
Prior art keywords
aqueous solution
composition
docetaxel
composition according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017560611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527287A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/032760 external-priority patent/WO2016187147A1/en
Publication of JP2018527287A publication Critical patent/JP2018527287A/ja
Publication of JP2018527287A5 publication Critical patent/JP2018527287A5/ja
Pending legal-status Critical Current

Links

JP2017560611A 2015-05-15 2016-05-16 ドセタキセルおよびヒト血清アルブミンの複合体 Pending JP2018527287A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562162545P 2015-05-15 2015-05-15
US62/162,545 2015-05-15
US201562209053P 2015-08-24 2015-08-24
US62/209,053 2015-08-24
US201662299209P 2016-02-24 2016-02-24
US62/299,209 2016-02-24
PCT/US2016/032760 WO2016187147A1 (en) 2015-05-15 2016-05-16 Docetaxel and human serum albumin complexes

Publications (2)

Publication Number Publication Date
JP2018527287A JP2018527287A (ja) 2018-09-20
JP2018527287A5 true JP2018527287A5 (enExample) 2019-06-20

Family

ID=57320749

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017560611A Pending JP2018527287A (ja) 2015-05-15 2016-05-16 ドセタキセルおよびヒト血清アルブミンの複合体

Country Status (5)

Country Link
US (2) US10500285B2 (enExample)
EP (1) EP3294286A4 (enExample)
JP (1) JP2018527287A (enExample)
CN (2) CN107683134B (enExample)
WO (1) WO2016187147A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10500285B2 (en) * 2015-05-15 2019-12-10 Zhuhai Beihai Biotech Co., Ltd. Docetaxel and human serum albumin complexes
WO2018035406A1 (en) * 2016-08-19 2018-02-22 Zhuhai Beihai Biotech Co., Ltd. Formulations of ibrutinib
US11419842B2 (en) 2016-10-27 2022-08-23 Zhuhai Beihai Biotech Co., Ltd. Neutral pH compositions of Docetaxel and human serum albumin
US20200061020A1 (en) * 2017-05-01 2020-02-27 Zhuhai Beihai Biotech Co., Ltd. Formulations and compositions of docetaxel
CN116747217B (zh) * 2018-04-11 2024-04-26 珠海贝海生物技术有限公司 多西他赛制剂和组合物
EP3866834A1 (en) 2018-10-17 2021-08-25 Sunstate Biosciences, LLC Single protein-encapsulated pharmaceutics for enhancing therapeutic effects
CN115297857B (zh) * 2020-02-04 2024-07-19 珠海贝海生物技术有限公司 多西他赛制剂
CN115400115B (zh) * 2021-05-26 2025-01-14 石药集团中奇制药技术(石家庄)有限公司 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途
CN113577267B (zh) * 2021-09-06 2022-04-08 江西北正干细胞生物科技有限公司 Nk细胞和抗体的药物组合物及其在治疗癌症中的用途
CA3252932A1 (en) * 2022-02-25 2025-03-03 Zhuhai Beihai Biotech Co., Ltd. Docetaxel compositions and methods
WO2024230772A1 (zh) * 2023-05-09 2024-11-14 江苏康宁杰瑞生物制药有限公司 包含抗her2双特异性抗体的联合治疗药物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216126A (ja) * 1982-06-11 1983-12-15 Ono Pharmaceut Co Ltd 可容化製剤
EP0932399B1 (en) * 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
IL141155A0 (en) * 1998-07-30 2002-02-10 Human Rt Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
CA2620308A1 (en) 2005-10-12 2007-04-19 Sicor Inc. Crystalline forms of docetaxel and processes for their preparation
KR20080100264A (ko) 2006-03-21 2008-11-14 닥터 레디스 레보러터리즈 리미티드 도세탁셀의 다형체와 그 제조방법
CA2756603C (en) 2006-10-20 2013-05-28 Scinopharm Singapore Pte, Ltd. Process for making crystalline docetaxel trihydrate
WO2008102374A1 (en) 2007-02-20 2008-08-28 Dabur Pharma Limited Amorphous form of docetaxel
KR100878455B1 (ko) 2007-04-10 2009-01-13 한미약품 주식회사 안정한 무수결정형 도세탁셀 및 이의 제조방법
US20100197944A1 (en) 2007-07-04 2010-08-05 Dr. Reddy's Laboratories Limited Docetaxel process and polymorphs
CN101357126A (zh) * 2008-08-11 2009-02-04 张文芳 一种稳定的紫杉烷类白蛋白脂质载药系统及其制备方法
CN101361731A (zh) * 2008-08-11 2009-02-11 张文芳 白蛋白稳定的多西紫杉醇冻干制剂及其在治疗肿瘤方面的应用
CN101658516B (zh) * 2008-08-26 2011-10-05 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
CZ303072B6 (cs) 2009-02-13 2012-03-21 Zentiva, K.S. Polymerní konjugáty paclitaxelu a docetaxelu s pH rízeným uvolnováním kancerostatika
KR101149600B1 (ko) 2009-12-31 2012-05-29 주식회사 삼양제넥스바이오 고순도 무수결정형 도세탁셀 제조방법
WO2011097149A2 (en) * 2010-02-03 2011-08-11 Oncbiomune, L.L.C. Taxane-and taxoid-protein compositions
CA2794147A1 (en) * 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
US8890233B2 (en) 2010-07-06 2014-11-18 Macronix International Co., Ltd. 3D memory array with improved SSL and BL contact layout
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
KR20120096200A (ko) 2011-02-22 2012-08-30 동아제약주식회사 결정형 도세탁셀 및 이의 제조방법
CN102688200B (zh) * 2012-05-09 2014-03-26 广州帝奇医药技术有限公司 植物类抗癌靶向纳米制剂及其制备方法
US9962452B2 (en) * 2013-02-04 2018-05-08 Zhuhai Beihai Biotech Co., Ltd. Soluble complexes of drug analogs and albumin
US10500285B2 (en) * 2015-05-15 2019-12-10 Zhuhai Beihai Biotech Co., Ltd. Docetaxel and human serum albumin complexes

Similar Documents

Publication Publication Date Title
JP2018527287A5 (enExample)
JP2018503668A5 (enExample)
JP2017105793A5 (enExample)
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
JP2018521135A5 (enExample)
JP2015078230A5 (enExample)
MX2017006649A (es) Derivados de triazolo-pirazinilo utiles como activadores de guanilato ciclasa soluble.
JP2014521688A5 (enExample)
AR080863A1 (es) Derivados del acido1-amino-2-ciclopropiletilboronico, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer.
JP2016510326A5 (enExample)
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
JP2016507575A5 (enExample)
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
HRP20220683T1 (hr) Liječenje parkinsonove bolesti
JP2018514522A5 (enExample)
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
AU2018269304A1 (en) Preparation of biologically active complexes
JP2015107945A5 (enExample)
CA2920410C (en) Thienopiperidine derivative and use thereof
CN109689652A (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
MX388073B (es) Composición farmacéutica, preparación y usos de la misma.
WO2015193517A3 (en) Liquid pharmaceutical composition comprising pemetrexed
EA201590474A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
RU2015156417A (ru) Лосмапимод для применения в лечении гломерулярного заболевания